Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Ozaki Y, Yokoe T, Yoshinami T, Nozawa K, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Ozaki Y, et al. Among authors: nozawa k. Int J Clin Oncol. 2024 May;29(5):551-558. doi: 10.1007/s10147-024-02499-y. Epub 2024 Mar 25. Int J Clin Oncol. 2024. PMID: 38526621
Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T. Yokoe T, et al. Among authors: nozawa k. Breast Cancer. 2021 May;28(3):581-591. doi: 10.1007/s12282-020-01192-y. Epub 2021 Jan 2. Breast Cancer. 2021. PMID: 33389616 Free PMC article.
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Matsubara Y, Masuishi T, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Bando H, Taniguchi H, Kadowaki S, Ando M, Tajika M, Muro K. Matsubara Y, et al. Among authors: nozawa k. J Cancer Res Clin Oncol. 2023 Mar;149(3):1123-1129. doi: 10.1007/s00432-022-03979-2. Epub 2022 Mar 22. J Cancer Res Clin Oncol. 2023. PMID: 35314873 Clinical Trial.
Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials.
Nozawa K, Takatsuka D, Endo Y, Horisawa N, Ozaki Y, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H. Nozawa K, et al. Crit Rev Oncol Hematol. 2022 Jun;174:103703. doi: 10.1016/j.critrevonc.2022.103703. Epub 2022 May 6. Crit Rev Oncol Hematol. 2022. PMID: 35533814 Review.
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Watanabe K, Maeda S, Yokoe T, Imamura CK, Matsumoto K, Iwasa T, Chiba Y, Takiguchi D, Takano T. Sakai H, et al. Among authors: nozawa k. BMJ Open. 2023 Apr 3;13(4):e070304. doi: 10.1136/bmjopen-2022-070304. BMJ Open. 2023. PMID: 37012013 Free PMC article.
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Ando Y, et al. Among authors: nozawa k. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. Int J Clin Oncol. 2023. PMID: 37453935
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Yoshinami T, Nozawa K, Yokoe T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Yoshinami T, et al. Among authors: nozawa k. Int J Clin Oncol. 2024 Jun;29(6):681-688. doi: 10.1007/s10147-024-02504-4. Epub 2024 Apr 23. Int J Clin Oncol. 2024. PMID: 38649648
444 results